Breakthrough designation for Tecentriq plus Avastin in liver cancer

19 July 2018
2019_biotech_test_vial_discovery_big

Swiss pharma giant Roche (ROG: SIX) has been awarded a Breakthrough Therapy badge for a combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) against hepatocellular carcinoma (HCC) in the first-line setting.

HCC is the most common form of liver cancer. Roche has been trialling a combination of its checkpoint inhibitor, Tecentriq, with its anti-VEGF biologic, Avastin, in a Phase Ib trial, results from which were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in June.

Those results showed that after a median follow-up of 10.3 months, responses were seen in 15 of 23 “efficacy-evaluable” patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology